European Journal of Cardiovascular Medicine

Cardiovascular diseases (CVDs) remain the foremost cause of global morbidity and mortality, accounting for nearly one-third of all deaths worldwide each year despite remarkable advances in diagnostic imaging, pharmacotherapy, and interventional techniques [1]. Conventional risk factors—hypertension, diabetes mellitus, dyslipidemia, smoking, and obesity—explain much of the burden; however, a substantial proportion of cardiovascular risk remains unexplained even after adjusting for these classical determinants [2,3]. Over the past decade, the human gut microbiota has emerged as an intriguing biological system capable of influencing cardiovascular physiology and disease through its extensive metabolic, immunologic, and endocrine interactions with the host [4–6].

The gut microbiota refers to the diverse and dynamic community of microorganisms inhabiting the gastrointestinal tract—comprising bacteria, archaea, viruses, and fungi—with an estimated cell count approaching 10¹⁴, outnumbering human cells by nearly tenfold [7]. This microbial ecosystem performs essential physiological functions: digestion of complex carbohydrates, synthesis of vitamins, metabolism of bile acids, modulation of intestinal barrier integrity, and regulation of immune homeostasis [8]. The intestinal microbiome behaves as a “metabolic organ,” communicating bidirectionally with distant tissues through microbial metabolites, hormonal mediators, and immune signaling pathways—a concept now central to the gut–heart axis [9].

Recent evidence suggests that alterations in the gut microbial composition and function (dysbiosis) are linked to major cardiometabolic disorders including hypertension, obesity, insulin resistance, and atherosclerosis [10–12]. Dysbiosis typically manifests as reduced microbial diversity, depletion of beneficial commensals (e.g., Bacteroides, Faecalibacterium), and enrichment of potentially pathogenic species (e.g., Enterobacteriaceae, Streptococcus) [13]. These microbial shifts influence the host metabolic milieu by producing bioactive compounds that either promote or protect against vascular injury.

Among the best-studied metabolites is trimethylamine N-oxide (TMAO), a hepatic oxidation product of trimethylamine (TMA) generated by microbial metabolism of dietary choline, phosphatidylcholine, and L-carnitine [14,15]. Elevated plasma TMAO levels have been strongly associated with increased risk of atherosclerosis, thrombosis, heart failure, and mortality in multiple human cohorts [16,17]. Mechanistic studies indicate that TMAO promotes foam-cell formation, enhances platelet reactivity, impairs reverse cholesterol transport, and induces endothelial dysfunction—key processes in atherogenesis [18]. Conversely, short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate, produced by microbial fermentation of dietary fibers, exert cardioprotective effects by maintaining gut barrier integrity, regulating blood pressure via G-protein-coupled receptors (GPR41, GPR43), and suppressing vascular inflammation [19–21].

Another important class of microbial metabolites includes secondary bile acids, which modulate cholesterol homeostasis and glucose metabolism through activation of nuclear receptors such as FXR and TGR5 [22]. Dysbiosis can disrupt bile acid pools, alter enterohepatic circulation, and influence lipid metabolism—all contributing to metabolic and vascular dysfunction. Additionally, bacterial endotoxins such as lipopolysaccharide (LPS) can translocate through a compromised intestinal barrier, activate Toll-like receptor 4 (TLR4), and trigger low-grade systemic inflammation, thereby promoting endothelial injury and plaque instability [23,24].

Experimental animal models provide strong mechanistic evidence supporting the causal role of gut microbiota in cardiovascular pathology. Germ-free mice are resistant to diet-induced atherosclerosis and angiotensin II-mediated hypertension, whereas transplantation of dysbiotic microbiota from hypertensive or obese donors induces similar phenotypes in recipient animals [25,26]. Furthermore, inhibition of microbial TMA formation or modulation of bile acid pathways significantly reduces atherosclerotic burden in animal studies [27,28]. These findings underscore the gut microbiome as an active participant—rather than a passive bystander—in the pathogenesis of CVD.

Human observational studies mirror these experimental observations. Patients with coronary artery disease, heart failure, and hypertension display distinct microbial signatures characterized by reduced diversity and altered abundance of key taxa [29]. Moreover, circulating TMAO concentrations independently predict adverse cardiovascular events, even after adjustment for established risk factors [16]. Such findings have prompted growing interest in therapeutically modulating the microbiome through diet, probiotics, prebiotics, synbiotics, and enzyme inhibitors targeting microbial TMA production [23,30]. Early clinical trials suggest that dietary fiber enrichment, plant-based diets, and probiotic supplementation can improve lipid profiles, reduce blood pressure, and attenuate systemic inflammation—effects likely mediated via microbiome-derived metabolites [20,21].

Despite these advances, major challenges remain. The interindividual variability of gut microbiota, complex host–microbe interactions, and limited causal data in humans complicate translation into clinical practice [17,25]. Standardization of sequencing methods, metabolomic analyses, and clinical endpoints is essential to establish reproducible associations. Furthermore, while microbial metabolites such as TMAO are robust biomarkers of cardiovascular risk, their direct causal role in human disease continues to be debated [15,17]. Large-scale prospective and interventional studies are therefore warranted to confirm mechanistic links and evaluate the therapeutic potential of microbiota-targeted strategies.

In summary, emerging evidence indicates that the gut microbiota represents a novel modifiable determinant of cardiovascular health. Through its metabolites and immunometabolic signaling pathways, the intestinal microbiome bridges diet, metabolism, and vascular function. Exploring this gut–heart axis not only enhances our understanding of CVD pathogenesis but also opens innovative avenues for prevention, risk stratification, and personalized therapy. This review aims to synthesize current knowledge regarding the role of gut microbiota, dysbiosis, and microbial metabolites in cardiovascular diseases, elucidate the underlying mechanisms, and discuss potential therapeutic interventions within this evolving paradigm.

Mechanistic Pathways Linking Gut Microbiota to Cardiovascular Health

The link between the gut microbiota and cardiovascular disease (CVD) is mediated by a complex interplay of metabolic, inflammatory, and neurohumoral pathways, collectively termed the gut–heart axis. These mechanisms integrate microbial metabolites, intestinal barrier function, immune activation, and host metabolic signaling. Understanding these mechanistic routes is vital for translating microbial insights into preventive and therapeutic strategies for cardiovascular disorders [1,4,10].

1. Intestinal Barrier Dysfunction and Endotoxemia

The intestinal epithelium forms a semi-permeable barrier that separates the luminal microbiota from systemic circulation. In dysbiosis, this barrier becomes compromised due to altered tight-junction proteins, mucosal inflammation, and reduced production of protective metabolites such as butyrate [8,19].

Loss of barrier integrity leads to bacterial translocation and leakage of microbial components—especially lipopolysaccharide (LPS)—into the bloodstream [23,24]. Circulating LPS binds to Toll-like receptor-4 (TLR4) on endothelial and immune cells, activating NF-κB signaling and releasing pro-inflammatory cytokines (IL-6, TNF-α, IL-1β). Chronic low-grade endotoxemia has been observed in obesity, diabetes, and heart failure, promoting vascular inflammation and atherogenesis [27].

Endotoxin exposure also reduces nitric-oxide (NO) bioavailability, induces oxidative stress, and increases expression of adhesion molecules such as VCAM-1 and ICAM-1, facilitating monocyte recruitment into the arterial wall [9,23]. Together, these processes create a pro-inflammatory vascular environment that accelerates plaque formation and instability.

2. Microbial Metabolites and Host Signaling

2.1 Trimethylamine N-oxide (TMAO)

The discovery of TMAO represents a landmark in cardio-microbiome research [2,14–17]. Dietary choline, phosphatidylcholine, and L-carnitine—abundant in red meat, eggs, and dairy—are metabolized by gut microbes via cutC/D and cntA/B enzymes to generate trimethylamine (TMA). Hepatic flavin mono-oxygenase-3 (FMO3) oxidizes TMA to TMAO, which enters systemic circulation [15].

Elevated plasma TMAO correlates with increased risk of myocardial infarction, stroke, and death independent of traditional risk factors [16]. Mechanistically, TMAO exerts multiple pro-atherogenic effects:

• Lipid metabolism: It suppresses reverse cholesterol transport by downregulating hepatic CYP7A1 and intestinal ABCA1, promoting cholesterol accumulation in macrophages [18].
• Platelet activation: TMAO enhances platelet responsiveness to agonists, increasing thrombosis potential [4,16].
• Endothelial dysfunction: TMAO impairs endothelial NO synthase activity and induces oxidative stress [15,18].
• Inflammation: It up-regulates scavenger receptors (CD36, SR-A1) and cytokines (IL-1β, IL-6), amplifying vascular inflammation [17].
•  

Animal models confirm causality: inhibition of microbial TMA formation (using 3,3-dimethyl-1-butanol or structural analogues) reduces circulating TMAO and atherosclerotic plaque burden [23]. Thus, TMAO serves both as a biomarker and potential mediator of CVD.

2.2 Short-Chain Fatty Acids (SCFAs)

SCFAs—acetate, propionate, and butyrate—are produced by bacterial fermentation of dietary fibers by genera such as Bacteroides, Roseburia, and Faecalibacterium [19–21]. They are absorbed via monocarboxylate transporters (MCT1/SMCT1) and influence cardiovascular physiology through multiple actions:

1. Vasoregulation: SCFAs bind G-protein-coupled receptors (GPR41, GPR43, Olfr78) on vascular smooth-muscle and renal juxtaglomerular cells, modulating vasodilation and renin release [8,20].
2. Anti-inflammatory effects: Butyrate promotes regulatory T-cell differentiation and inhibits histone-deacetylases, thereby reducing cytokine expression and vascular inflammation [19].
3. Energy metabolism: SCFAs activate AMP-activated protein kinase (AMPK) in hepatocytes, enhancing lipid oxidation and improving insulin sensitivity [15,21].
4. Barrier protection: Butyrate is the primary energy source for colonocytes, reinforcing tight junctions and reducing endotoxin leakage [9].

Clinical studies show inverse associations between fecal SCFA levels and blood pressure or systemic inflammation [20]. Thus, SCFAs represent protective mediators counterbalancing TMAO’s deleterious actions.

2.3 Bile-Acid Signaling

Gut microbes deconjugate primary bile acids and convert them into secondary forms such as deoxycholic and lithocholic acid [18,22]. These metabolites interact with nuclear receptors FXR and TGR5, influencing cholesterol metabolism, glucose regulation, and vascular tone.

• Activation of FXR reduces hepatic triglyceride synthesis and modulates LDL receptor expression.
• TGR5 activation in macrophages and endothelial cells exerts anti-inflammatory effects through cAMP signaling [22].
• Dysbiosis may disturb the bile-acid pool, leading to impaired lipid handling and increased oxidative stress—both relevant to atherosclerosis [23].

Hence, bile-acid metabolism acts as an important biochemical bridge between the gut microbiota and systemic metabolic control.

2.4 Uremic Toxins and Indole Derivatives

In patients with chronic kidney disease (CKD)—a condition closely intertwined with CVD—gut microbial metabolism produces indoxyl sulfate and p-cresyl sulfate, derived from tryptophan and tyrosine fermentation [18]. These uremic toxins accumulate in plasma due to reduced renal clearance and promote endothelial dysfunction, vascular calcification, and cardiac fibrosis.

Another compound, phenylacetylglutamine (PAGln), has been linked to enhanced platelet activation and cardiovascular events via adrenergic receptor signaling [16].

Such findings highlight how microbiota-derived metabolites can directly impact renal-cardiovascular cross-talk, contributing to adverse outcomes in CKD and heart failure.

3. Immune and Inflammatory Crosstalk

The gut microbiota profoundly shapes both innate and adaptive immunity. Commensal microbes induce tolerance by stimulating regulatory T cells (Tregs) and producing anti-inflammatory cytokines (IL-10, TGF-β). Conversely, dysbiosis drives pro-inflammatory Th17 responses, enhancing IL-17 and IFN-γ production [27].

Microbial components—including peptidoglycans, flagellin, and unmethylated CpG DNA—activate pattern-recognition receptors such as TLRs and NOD-like receptors. This triggers downstream inflammatory cascades, endothelial activation, and monocyte adhesion, all central to atherogenesis [23,24].

Furthermore, microbiota-dependent activation of macrophages in the gut and spleen increases circulating inflammatory mediators that reach the myocardium, promoting remodeling and dysfunction in heart failure models [20]. Chronic inflammation also alters vascular smooth-muscle cell phenotype, favoring plaque instability and thrombosis.

4. Neurohumoral and Metabolic Signaling

The gut–brain–heart axis describes bidirectional communication between intestinal microbiota, the autonomic nervous system, and cardiovascular control centers [19]. SCFAs can influence vagal afferent signaling, modulating sympathetic outflow and thus blood-pressure regulation [8]. Dysbiosis-induced inflammation may activate the hypothalamic–pituitary–adrenal axis, raising cortisol and catecholamines, which in turn affect endothelial function and myocardial workload.

Metabolites such as TMAO and bile acids also influence hepatic glucose and lipid metabolism, thereby indirectly altering cardiovascular risk factors such as dyslipidemia, insulin resistance, and obesity [14,21]. Collectively, these neurohumoral interactions demonstrate that the microbiota acts as a systemic endocrine organ influencing cardiovascular regulation beyond local gut effects.

5. Microbiota and Hypertension

Compelling evidence links microbial alterations to blood-pressure dysregulation. Hypertensive humans and animal models exhibit reduced microbial diversity, depletion of acetate- and butyrate-producing species, and enrichment of lactate-producing bacteria [7,8].

SCFAs—especially acetate and propionate—exert antihypertensive actions via GPR41 and Olfr78 signaling, modulating vascular resistance and renin secretion [20]. Conversely, high-salt intake alters gut microbial composition, depleting Lactobacillus murinus and promoting Th17-mediated hypertension [28].

Interventions restoring microbial balance (fiber supplementation, probiotics) lower blood pressure and improve endothelial function in both experimental and early human studies [7,8,19]. Hence, gut dysbiosis contributes directly to hypertension through metabolic, inflammatory, and neural mechanisms.

6. Microbiota and Atherosclerosis

Atherosclerosis—the central pathological process in coronary artery disease—entails lipid deposition, inflammation, and fibrosis within the arterial wall. The microbiome contributes through multiple converging mechanisms:

• TMAO pathway: promotes lipid accumulation and macrophage foam-cell formation [15–18].
• LPS translocation: induces vascular inflammation and endothelial activation [23].
• Bile-acid dysregulation: alters cholesterol metabolism and bile excretion [18,22].
• Immune activation: shifts T-cell balance toward pro-atherogenic Th1/Th17 responses [27].

Histological and metagenomic analyses reveal bacterial DNA within atherosclerotic plaques, suggesting possible microbial colonization or molecular mimicry contributing to plaque inflammation [6,10].
Collectively, these findings position the gut microbiota as a key upstream regulator of atherogenesis and its clinical manifestations.

7. Heart Failure and Myocardial Remodeling

In chronic heart failure (HF), intestinal hypoperfusion and congestion result in mucosal ischemia, increased permeability, and bacterial translocation [24]. Circulating endotoxins stimulate systemic inflammation and cytokine release (IL-6, TNF-α), exacerbating myocardial remodeling and progression of HF [20,24].

Moreover, elevated TMAO levels in HF patients correlate with adverse outcomes and higher mortality, suggesting a metabolic component to disease progression [16,24]. In animal models, modulation of gut flora with probiotics or antibiotics ameliorates inflammation and improves ventricular function [25]. Thus, a vicious cycle arises: HF induces gut dysbiosis, which in turn aggravates cardiac dysfunction via inflammatory and metabolic pathways.

8. Integrative Perspective

The cumulative evidence supports a multi-layered mechanistic model:

1. Microbial Dysbiosis: Alters the abundance of beneficial and pathogenic taxa.
2. Metabolic Derangements: Increased TMAO and reduced SCFAs perturb lipid and glucose metabolism.
3. Barrier Breakdown: LPS leakage fuels systemic inflammation.
4. Immune Activation: Cytokine release and endothelial injury amplify vascular damage.
5. Neurohumoral Feedback: Sympathetic overactivity and metabolic stress exacerbate hypertension and cardiac remodeling.

This integrated network forms a self-reinforcing cycle connecting intestinal ecology to vascular pathology and cardiac outcomes. It underpins the concept that the microbiota functions as an endocrine and immune organ influencing cardiovascular homeostasis [9,13,20].

9. Therapeutic Implications

Understanding these pathways opens avenues for targeted interventions:

• Dietary modulation: High-fiber, plant-based, and Mediterranean diets enhance SCFA-producing species and reduce TMAO precursors [19–21].
• Probiotics and prebiotics: Restore microbial balance and improve vascular biomarkers.
• Enzyme inhibitors: Target microbial TMA lyases (cutC/D) or host FMO3 to lower TMAO production [23].
• Bile-acid receptor agonists (FXR/TGR5): Modulate lipid metabolism and inflammation [22].
• Anti-inflammatory strategies: Reduce LPS-TLR4 signaling and preserve endothelial integrity [24].

Future precision-microbiome therapies may integrate metagenomic and metabolomic profiling to tailor interventions for individual cardiovascular risk phenotypes.

Therapeutic Modulation and Future Directions

Growing evidence linking gut dysbiosis with cardiovascular disease (CVD) has stimulated intensive research into microbiota-targeted therapies as adjuncts to conventional preventive and pharmacologic strategies. The aim is to restore intestinal eubiosis, reduce generation of atherogenic metabolites such as trimethylamine N-oxide (TMAO), and enhance production of beneficial compounds such as short-chain fatty acids (SCFAs). This section discusses current and emerging approaches for manipulating the gut–heart axis and highlights challenges and future prospects for clinical translation.

1. Dietary Interventions: The Foundational Strategy

Diet remains the single most potent determinant of microbial composition and function. Long-term dietary patterns influence the relative abundance of major bacterial phyla—Firmicutes, Bacteroidetes, and Actinobacteria—and thereby modulate cardiometabolic risk factors [8,19].

1.1 High-Fiber and Plant-Based Diets

Dietary fibers act as prebiotics, fueling fermentation by SCFA-producing bacteria (Bifidobacterium, Faecalibacterium, Roseburia). The resulting acetate, propionate, and butyrate enhance intestinal integrity, down-regulate inflammatory cytokines, and favorably influence blood pressure and lipid metabolism [19–21]. Clinical studies demonstrate that increased fiber intake reduces serum cholesterol and systemic inflammation while improving endothelial function [20].

Plant-based and Mediterranean diets, rich in polyphenols, unsaturated fats, and antioxidants, are consistently associated with lower cardiovascular mortality. These diets shift microbial metabolism toward SCFA production and away from TMAO generation [19]. Polyphenols such as resveratrol and catechins exert additional prebiotic-like effects by stimulating Lactobacillus and Bifidobacterium growth while inhibiting pathogenic taxa [9,19].

1.2 Reduction of TMAO Precursors

Limiting consumption of choline- and carnitine-rich foods (red meat, egg yolks, dairy) decreases substrate availability for TMA formation [14–17]. In interventional studies, replacement of red meat with plant protein or fish lowers circulating TMAO and reduces platelet hyperreactivity [16]. Although strict elimination diets are impractical, moderate restriction combined with fiber-rich intake achieves a more balanced microbial output.

1.3 Salt and Fat Intake

High-salt diets reduce beneficial Lactobacillus species and promote Th17-mediated hypertension [28]. Similarly, high saturated-fat intake favors bile-tolerant pro-inflammatory microbes (Bilophila wadsworthia). Conversely, diets rich in unsaturated fatty acids support eubiosis and reduce systemic inflammation [19,20].

2. Probiotics, Prebiotics, Synbiotics, and Postbiotics

2.1 Probiotics

Probiotics—live microorganisms conferring health benefits—are widely investigated for their cardiovascular effects. Lactobacillus plantarum, L. reuteri, and Bifidobacterium longum strains reduce serum LDL, attenuate inflammation, and improve blood pressure in small clinical trials [19,20]. The mechanisms include bile-salt hydrolase activity, SCFA generation, and competitive inhibition of pathogenic taxa.

Meta-analyses suggest modest but significant reductions in total cholesterol (≈ 8 mg/dL) and systolic blood pressure (≈ 3 mmHg) with specific probiotic supplementation [8]. Despite heterogeneity, these findings indicate a potential supportive role for probiotics in CVD prevention.

2.2 Prebiotics and Synbiotics

Prebiotics—non-digestible substrates such as inulin, fructo-oligosaccharides (FOS), and galacto-oligosaccharides (GOS)—selectively enhance beneficial microbes. Synbiotics combine probiotics and prebiotics, creating synergistic effects. In metabolic-syndrome cohorts, synbiotic therapy improves lipid profiles, fasting glucose, and markers of oxidative stress [21].

2.3 Postbiotics

Postbiotics refer to non-viable microbial components or metabolites (e.g., butyrate, lactate, exopolysaccharides) with health benefits. Direct administration of butyrate or its analogues reinforces barrier integrity and exerts anti-inflammatory actions without colonization risks. Postbiotic therapy is an emerging field with promising experimental evidence [19,21].

3. Fecal Microbiota Transplantation (FMT)

FMT involves infusion of processed stool from a healthy donor into the recipient’s gut to restore microbial balance. It is established for recurrent Clostridioides difficile infection, and exploratory studies extend its use to metabolic syndrome, obesity, and CVD risk modulation [24,25].

Animal models demonstrate that transferring microbiota from lean or normotensive donors reduces adiposity and blood pressure, respectively [26,28]. However, human cardiovascular applications remain preliminary. Major limitations include:

• Safety concerns: risk of pathogen transmission and unpredictable immune reactions.
• Donor selection: identifying optimal microbial profiles.
• Durability: transient colonization often limits sustained benefit.

Future refinements—such as defined microbial consortia or encapsulated FMT preparations—may enhance safety and reproducibility [25].

4. Pharmacologic Modulation of Microbial Metabolism

Targeting microbial enzymes and host metabolic pathways offers precise control of pathogenic metabolites like TMAO.

4.1 Inhibition of Microbial TMA Formation

Small-molecule inhibitors of bacterial TMA-lyase (cutC/D) or carnitine mono-oxygenase (cntA/B) suppress TMA generation without killing the bacteria, preserving overall microbiome structure.

• Compounds such as 3,3-dimethyl-1-butanol (DMB) and structural analogs significantly lower plasma TMAO and atherosclerosis in mice [23].
• Next-generation enzyme blockers and probiotics expressing TMA-lyase antagonists are under development.

4.2 Host-Enzyme and Receptor Modulation

Down-regulation of hepatic FMO3, responsible for TMA oxidation, has been proposed as a secondary strategy. However, systemic inhibition may produce off-target hepatic effects [17].

4.3 Bile-Acid Receptor Agonists

Activation of FXR and TGR5 receptors by bile-acid analogues or agonists modulates lipid metabolism, reduces triglycerides, and exerts anti-inflammatory actions [22]. FXR agonists (obeticholic acid, cilofexor) and dual FXR/TGR5 agents are under study for metabolic and cardiovascular endpoints.

4.4 Targeting Inflammation and Barrier Dysfunction

Agents that restore intestinal barrier integrity—such as butyrate donors, L-glutamine, or tight-junction modulators—reduce endotoxemia and systemic inflammation [23,24]. Additionally, selective TLR4 antagonists and anti-cytokine therapies may mitigate the vascular consequences of microbial translocation [27].

5. Microbiota–Drug Interactions

Microbial enzymes can alter drug bioavailability and efficacy. For example:

• Statins and metformin partially exert cardiometabolic benefits via modulation of gut flora [26].
• Some microbes deactivate digoxin or metabolize aspirin, influencing therapeutic response.
  Recognizing these pharmacomicrobiomic interactions may enable personalized drug dosing based on an individual’s microbial signature. Future pharmacogenomic models should incorporate microbial metabolic capacity as a covariate.

6. Emerging Frontiers

6.1 Precision and Personalized Microbiome Therapy

Each individual harbors a unique microbial “fingerprint,” suggesting that one-size-fits-all interventions are suboptimal. Integration of multi-omics approaches—metagenomics, metabolomics, and transcriptomics—enables identification of responders and tailored therapy [17,25]. Machine-learning algorithms using microbiome profiles may soon predict cardiovascular risk and treatment response with higher accuracy than traditional biomarkers.

Table 1. Comparative Summary of Major Studies Exploring the Gut–Heart Connection

6.2 Engineered Microbes and Next-Generation Probiotics

Synthetic-biology approaches now allow design of engineered bacterial strains capable of consuming TMA, secreting SCFAs, or delivering therapeutic peptides. Escherichia coli Nissle 1917 and Bacteroides fragilis are being reprogrammed for this purpose [23]. These “living biotherapeutics” promise precision delivery of metabolites while minimizing systemic toxicity.

6.3 Metabolite Supplementation and Nutraceuticals

Direct supplementation with beneficial metabolites—e.g., sodium butyrate, propionate salts, or polyphenol-derived microbial metabolites—represents a novel postbiotic therapy. Early-phase trials show improvements in insulin sensitivity and vascular markers, but long-term cardiovascular outcomes remain untested [19,21].

6.4 Microbiome Biomarkers for Risk Stratification

Quantifying microbial metabolites (TMAO, PAGln, SCFAs) in plasma offers a non-invasive biomarker panel for early detection and prognostication of CVD [16]. Integration with genomic and metabolomic data may refine risk prediction models beyond traditional scoring systems.

7. Challenges and Limitations

Despite significant promise, microbiome-targeted therapy faces critical challenges:

1. Causality vs Association: Most human studies are correlational; establishing direct causal effects demands randomized controlled trials with mechanistic endpoints [1,17].
2. Inter-Individual Variability: Microbiota composition varies by diet, genetics, ethnicity, and geography, complicating standardization [13].
3. Safety and Regulation: Live microbial therapies and FMT raise regulatory concerns regarding contamination, horizontal gene transfer, and long-term ecological shifts [24,25].
4. Durability of Effect: Microbiome changes may revert after discontinuation of intervention. Sustained modulation strategies are needed.
5. Measurement and Standardization: Inconsistent sequencing platforms and analytic pipelines impede reproducibility across studies [17,25].
6. Translational Gap: Most evidence stems from animal models; human trials with hard cardiovascular outcomes (MI, stroke, mortality) are scarce.

Addressing these challenges will require rigorous clinical design, standardized methodologies, and multidisciplinary collaboration between cardiologists, microbiologists, and computational biologists.

1. Overview The past decade has witnessed a paradigm shift in cardiovascular medicine with the recognition that the gut microbiota functions as a metabolic and immunologic organ, influencing the pathogenesis of cardiovascular diseases (CVDs). Once viewed primarily as a digestive symbiont, the intestinal microbiome is now recognized as a central player in systemic homeostasis, capable of modulating vascular tone, lipid metabolism, and inflammatory signaling through its diverse metabolites and host interactions [1,4,17]. This review synthesizes mounting evidence that links microbial dysbiosis with the initiation and progression of atherosclerosis, hypertension, and heart failure, thereby introducing the gut–heart axis as a critical biological framework in preventive cardiology. 2. Integration of Mechanistic Pathways The association between the gut microbiome and cardiovascular health is multifaceted, encompassing metabolic, inflammatory, and neurohumoral dimensions. Among microbial metabolites, trimethylamine N-oxide (TMAO) is the most consistently linked to CVD risk. Elevated TMAO levels correlate with increased incidence of myocardial infarction, stroke, and mortality [14–17]. Mechanistically, TMAO promotes foam-cell formation, enhances platelet aggregation, and impairs endothelial function, thereby amplifying atherothrombotic risk [16,18]. Conversely, short-chain fatty acids (SCFAs)—notably acetate, propionate, and butyrate—exert cardioprotective effects by maintaining intestinal barrier integrity, activating anti-inflammatory signaling via GPR41/43, and enhancing nitric oxide bioavailability [19–21]. Bile-acid derivatives and indolic compounds further modulate cholesterol metabolism, glucose regulation, and vascular tone through FXR/TGR5 and other receptor-mediated mechanisms [22,23]. Beyond metabolites, dysbiosis-driven intestinal permeability and translocation of lipopolysaccharide (LPS) contribute to chronic low-grade inflammation, a hallmark of atherogenesis and heart failure [23,24]. These mechanisms integrate at the endothelial level, where inflammatory cytokines and oxidative stress promote plaque formation and vascular dysfunction. Collectively, these pathways affirm that microbial composition directly orchestrates cardiovascular physiology through metabolic and immune cross-talk. 3. Evidence from Experimental and Clinical Studies Experimental data from germ-free and antibiotic-treated animal models confirm a causal role for gut microbiota in modulating CVD risk. Germ-free mice exhibit resistance to diet-induced obesity and atherosclerosis, while colonization with dysbiotic microbiota restores disease phenotypes [25–27]. Inhibition of microbial TMA synthesis markedly reduces plasma TMAO levels and atherosclerotic plaque burden [23]. Human studies corroborate these findings. Patients with coronary artery disease, hypertension, or heart failure consistently display altered microbial diversity and enrichment of pro-inflammatory species such as Enterobacteriaceae and Streptococcus [6,7,29]. Elevated TMAO and phenylacetylglutamine (PAGln) levels predict adverse cardiovascular outcomes independent of traditional risk factors [16,30]. Additionally, hypertensive individuals show depletion of SCFA-producing taxa (Faecalibacterium prausnitzii, Roseburia) and reduced fecal butyrate levels [8,20]. Nevertheless, most human evidence remains associative. Variability in diet, geography, and sequencing methodologies complicates causal inference. Randomized controlled trials with mechanistic endpoints are urgently needed to validate microbiome-targeted strategies as viable interventions in CVD. 4. Therapeutic Translation and Clinical Implications Modulation of the gut microbiome offers a promising adjunct to conventional CVD prevention strategies. Dietary interventions—particularly high-fiber, plant-based, and Mediterranean patterns—consistently enhance SCFA-producing taxa while reducing TMAO precursors [19–21]. These effects complement lipid-lowering and anti-inflammatory benefits already recognized in cardiology. Probiotic and synbiotic formulations provide modest improvements in lipid profiles and blood pressure, although heterogeneity in strain selection and dosing limits generalization [19,20]. Fecal microbiota transplantation (FMT) remains experimental but demonstrates potential for metabolic reprogramming and blood pressure modulation in early studies [25,26]. Pharmacologic inhibition of microbial TMA-lyase activity (e.g., 3,3-dimethyl-1-butanol) or host FMO3 enzyme function reduces TMAO production in preclinical models [23]. However, translating these enzyme inhibitors into safe human therapies requires further pharmacodynamic and toxicologic evaluation. Additionally, existing cardiometabolic drugs such as metformin and statins exert partial efficacy via microbiota modulation, highlighting the therapeutic potential of pharmacomicrobiomics—the study of drug–microbiome interactions [26]. Integration of microbial signatures into pharmacotherapy may enable personalized cardiovascular treatment based on an individual’s gut profile. 5. The Gut–Heart Axis as a Systems Network The gut–heart connection exemplifies a systems biology network, wherein microbial metabolites act as endocrine-like mediators linking diet, metabolism, and vascular health. The gut microbiome communicates with the host through three primary interfaces: 1. Metabolic: Regulating lipid, glucose, and bile-acid metabolism. 2. Immune: Shaping systemic inflammatory responses. 3. Neurohumoral: Modulating sympathetic and parasympathetic tone through the gut–brain axis [8,19]. Such multidimensional regulation implies that cardiovascular disease is not merely a vascular pathology but a manifestation of whole-system dysregulation involving microbial, metabolic, and immune networks. Consequently, microbiota-targeted interventions may achieve broader metabolic and vascular stabilization than isolated pharmacologic approaches. 6. Challenges and Gaps in Current Knowledge Despite growing enthusiasm, several unresolved questions temper the translational momentum of microbiome research: • Causality vs. correlation: While animal studies demonstrate causality, human data remain largely observational. • Microbiome variability: Each individual’s microbial ecosystem is shaped by genetics, diet, medications, and environment, complicating therapeutic standardization [13,17]. • Short-term vs. sustained effects: Many interventions produce transient microbial changes that revert after discontinuation. Sustained modulation strategies are needed. • Safety concerns: Long-term effects of probiotics, engineered microbes, or FMT are not fully understood. Regulatory frameworks must ensure quality and biosafety [24,25]. • Methodological heterogeneity: Differences in sequencing platforms, bioinformatic pipelines, and dietary control confound reproducibility across studies [17]. • Endpoints: Most human trials focus on surrogate markers (lipids, inflammation) rather than hard outcomes such as myocardial infarction, stroke, or mortality. To overcome these barriers, future research must employ multi-omics integration, standardized analytic pipelines, and large-scale prospective cohorts linking microbial shifts with clinical endpoints [25]. 7. Future Research Directions Advancing the field of cardio-microbiome science requires strategic focus on the following directions: 1. Mechanistic Elucidation: High-resolution metabolomic studies to quantify microbial metabolite flux and identify novel signaling molecules beyond TMAO and SCFAs. 2. Personalized Microbiome Medicine: Development of predictive algorithms incorporating microbiome data to customize diet and pharmacologic therapy. 3. Longitudinal Human Cohorts: Tracking dynamic microbial changes preceding CVD onset to establish temporal causality. 4. Microbial Biomarkers: Validation of plasma TMAO, PAGln, and SCFA ratios as predictive or prognostic biomarkers integrated into existing cardiovascular risk scores [16]. 5. Clinical Trials: Large-scale RCTs testing dietary, probiotic, or enzyme-inhibition interventions with hard endpoints (e.g., major adverse cardiac events). 6. Synthetic Biology and Engineered Strains: Development of live biotherapeutics engineered to degrade TMA, produce SCFAs, or secrete anti-inflammatory molecules [23]. 7. Holistic Systems Approach: Integration of diet, microbiota, metabolome, immune system, and neuroendocrine factors within a unified cardiometabolic model. Such initiatives will enable the transformation of the gut–heart axis from a conceptual framework to an actionable target in cardiovascular prevention. 8. Clinical Relevance For clinicians, understanding the gut–heart axis provides new insights into risk stratification and prevention. Measurement of TMAO and other microbial metabolites may complement existing biomarkers such as LDL, hs-CRP, or HbA1c. Lifestyle recommendations emphasizing plant-based, fiber-rich diets align both with cardiovascular and microbial health goals. Probiotic supplementation may serve as an adjunct in hypertensive or dyslipidemic patients intolerant to high-dose pharmacotherapy [8,19,20]. Moreover, microbiota modulation may explain interindividual variability in drug response—such as statin efficacy or clopidogrel metabolism—paving the way for microbiome-guided precision therapeutics [26]. Recognizing the gut microbiome as a therapeutic target enriches the clinical toolkit of cardiologists, integrating nutrition, pharmacology, and microbiology into a unified management approach.

The gut microbiota represents a dynamic and influential ecosystem that extends its impact well beyond the gastrointestinal tract, shaping cardiovascular health through metabolic, immunologic, and neurohumoral pathways. Dysbiosis—characterized by imbalance in microbial diversity and metabolite production—emerges as a critical driver of atherosclerosis, hypertension, and heart failure.

Microbial metabolites such as TMAO, SCFAs, bile acids, and LPS serve as molecular messengers linking the gut to the heart, mediating both protective and pathogenic effects [14–24].

Therapeutic strategies aiming to restore microbial equilibrium—ranging from diet and probiotics to enzyme inhibitors and engineered microbes—hold promise in reducing cardiovascular risk. However, rigorous clinical validation, long-term safety data, and personalized frameworks are essential for integration into mainstream practice.

In the era of precision medicine, the gut–heart connection signifies a transformative frontier in cardiology—redefining disease not solely as vascular pathology but as a systemic interplay between human and microbial physiology. As research continues to unravel this symbiotic relationship, microbiota-based interventions may revolutionize cardiovascular prevention, heralding a new era of microbial cardiometabolic medicine.

1.      Tang WHW, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest. 2014;124(10):4204-11.

2.      Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63.

3.      Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576-85.

4.      Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165(1):111-24.

5.      Karlsson FH, Fåk F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245.

6.      Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. 2017;8:845.

7.      Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, et al. Gut microbiota dysbiosis contributes to hypertension. Hypertension. 2017;69(4):651-9.

8.      Marques FZ, Mackay CR, Kaye DM. Beyond gut feelings: how the gut microbiota regulates blood pressure. Nat Rev Cardiol. 2018;15(1):20-32.

9.      Chen ML, Yi L, Zhang Y, Zhou X, Ran L, Yang J, et al. Resveratrol attenuates trimethylamine-N-oxide–induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism. J Am Heart Assoc. 2016;5(8):e003347.

10.   Org E, Mehrabian M, Lusis AJ. Unraveling the environmental and genetic interactions in atherosclerosis: central role of the gut microbiota. Atherosclerosis. 2015;241(2):387-99.

11.   Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 2004;101(44):15718-23.

12.   Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575-84.

13.   Brown JM, Hazen SL. The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu Rev Med. 2015;66:343-59.

14.   Zhao L. The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol. 2013;11(9):639-53.

15.   Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Võsa U, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet. 2019;51(4):600-5.

16.   Li XS, Obeid S, Klingenberg R, Gencer B, Mach F, Räber L, et al. Gut microbiota–dependent trimethylamine N-oxide in atherosclerosis and thrombosis. Eur Heart J. 2017;38(31):2313-20.

17.   Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Circ Res. 2020;127(4):553-70.

18.   Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 2016;7(1):22-39.

19.   Karlsson FH, Tremaroli V, Bäckhed F. Human gut microbiota and cardiovascular risk. Proc Nutr Soc. 2013;72(1):72-80.

20.   Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol. 2019;16(3):137-54.

21.   Trøseid M, Andersen GØ, Broch K, Hov JR. The gut microbiome in coronary artery disease and heart failure: current knowledge and future directions. EBioMedicine. 2020;52:102649.

22.   Kasahara K, Krautkramer KA, Org E, Romano KA, Kerby RL, Vivas EI, et al. Interactions between gut microbiota, host genetics and diet modulate the predisposition to obesity and metabolic syndrome. Cell Metab. 2018;27(3):588-600.

23.   Gupta N, Buffa JA, Roberts AB, Sangwan N, Skye SM, Li L, et al. Targeted inhibition of gut microbial trimethylamine production for the prevention of atherosclerosis. Eur Heart J. 2020;41(9):813-22.

24.   Tang WHW, Wang Z, Shrestha K, Borowski AG, Wu Y, Troughton RW, et al. Intestinal microbiota–dependent phosphatidylcholine metabolites and heart failure outcomes. J Am Coll Cardiol. 2015;65(10):1041-51.

25.   Lin H, An Y, Hao F, Wang Y, Tang H. Correlations of fecal metabonomic and microbiomic changes induced by high-fat diet in the pre-obesity state. Sci Rep. 2016;6:21618.

26.   Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe. 2015;17(5):690-703.

27.   Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-74.

28.   Wilck N, Matus MG, Kearney SM, Olesen SW, Forslund K, Bartolomaeus H, et al. Salt-responsive gut commensal modulates TH17 axis and disease. Nature. 2017;551(7682):585-9.

29.   Kelly TN, Bazzano LA, Ajami NJ, He H, Zhao J, Petrosino JF, et al. Gut microbiome associates with lifetime cardiovascular risk profile among Bogalusa Heart Study participants. Circ Res. 2016;119(8):956-64.

Tang WHW, Hazen SL. Microbiome, trimethylamine N-oxide, and cardiometabolic disease. Transl Res. 2017;179:108-15.